# Build better medicines through evidence, consistency, and safety Established narrow medical uses · New indications require evidence. Specific cannabinoid medicines have specific evidence. The US FDA has approved purified cannabidiol for certain seizure disorders; that does not validate every cannabis preparation or establish Philippine approval. Select the first indication through an independent review of clinical evidence, unmet patient need, alternatives, and local feasibility. Include adverse effects and interactions in the same review as potential benefits. Canonical page: https://givegigs.com/wiki/necro-chapter-cannabis-medical-evidence Last updated: 2026-11-09T18:58:12.584Z Parent topic: [necromancer-cannabis](https://givegigs.com/wiki/necromancer-cannabis) ## Contents - [Overview](#wiki-section-overview-1) - [Chapter notes](#wiki-section-chapter-notes-2) - [Dossier section](#wiki-section-dossier-link-3) ## Overview Established narrow medical uses · New indications require evidence. This page expands the “Build better medicines through evidence, consistency, and safety” chapter in the cannabis collection. ## Chapter notes Specific cannabinoid medicines have specific evidence. The US FDA has approved purified cannabidiol for certain seizure disorders; that does not validate every cannabis preparation or establish Philippine approval. Select the first indication through an independent review of clinical evidence, unmet patient need, alternatives, and local feasibility. Include adverse effects and interactions in the same review as potential benefits. The proposed centers should compare verified product composition and quality rather than treat strain names as standardized interventions. Qualified laboratories would assess identity, consistency, contaminants, stability, and the suitability of each product for its intended study. A Philippine formulation cannot be assumed equivalent to a US product because both carry a cannabis label. Making cannabis better with technology should mean reproducible quality, clearer therapeutic benefit, lower avoidable harm, and affordable access. Higher potency is not itself progress. Require a product-specific development plan, independent verification, and a publication record that includes failures before making efficacy or superiority claims in either country. ## Dossier section [Open this exact section in the Necromancer dossier](/necromancer#cannabis-medical-evidence). The original chapter status is “Established narrow medical uses · New indications require evidence.” ## Sources - [Cannabis and cannabis-derived compounds: evidence and risks](https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis) --- This article is collaboratively maintained. Check the canonical page and cited sources for the latest context.